EUVIMEDEUVIMED entdecken
Crossref

Discovery of Pyrazoloquinazoline Analogues as Orally Bioavailable KRAS-G12D Inhibitors

Jiyoung Song, Eunsung Jang, Gyeonghi Cho, Hoiyun Jung, Minchang Cho, Chuneung Park, Jihun Kim, Soyoung Ki, Beomjin Hong, Ilkyoo Koh, Hyunho Cho, Seona Lim und 5 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Jiyoung Song und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Quinazolines, Antineoplastic Agents, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, SK Biopharmaceuticals Co, Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

G12D is a dominant mutant of KRAS, accounting for 67.6% of PDAC cases, which drives the development of selective KRAS-G12D inhibitors in cancer therapy. Herein, we describe the rationale design, synthesis, and biological evaluation of KRAS-G12D inhibitors with pyrazoloquinazoline and 3,5-ethylene-bridged piperazine groups as the key pharmacophores. Compound 53a exhibited comparable binding to KRAS-G12D (ΔTm = 12.1 °C) and potent in vitro activities (IC50 values of 8.4 nM and 19.5 nM against p-ERK and proliferation of AsPC-1 cells, respectively), compared to those of MRTX1133 as a reference standard. Furthermore, compound 53a displayed appreciable plasma exposure, bioavailability, and pharmacokinetic profiles after oral administration, overcoming the poor oral bioavailability observed in MRTX1133. In vivo study showed that 53a significantly inhibited tumor growth in the AsPC-1 xenograft mouse model by inhibiting KRAS-G12D. These findings support 53a as a promising lead candidate for the development of selective KRAS-G12D targeted cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)QuinazolinesAntineoplastic AgentsPyrazolesDrug DiscoveryProtein Kinase InhibitorsAnimalsHumansAdministration, OralBiological AvailabilityMiceCell Line, TumorStructure-Activity RelationshipCell ProliferationXenograft Model Antitumor AssaysMice, NudeRats

Substanzen

Proto-Oncogene Proteins p21(ras)QuinazolinesAntineoplastic AgentsKRAS protein, humanPyrazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
  • Drug Research Division, SK Biopharmaceuticals Co., Ltd., Seongnam 13494, Republic of Korea.

ORCID-Profile: Hyun-Ju Park, Pargat Singh, In Su Kim

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea
  • SK Biopharmaceuticals Co, Ltd.

Zitieren

APA

Song, J., Jang, E., Cho, G., Jung, H., Cho, M., Park, C., Kim, J., Ki, S., Hong, B., Koh, I., Cho, H., Lim, S., Moon, M. J., Hwang, S., Park, H. J., Singh, P., & Kim, I. S. (2025). Discovery of Pyrazoloquinazoline Analogues as Orally Bioavailable KRAS-G12D Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02840

Vancouver

Song J, Jang E, Cho G, Jung H, Cho M, Park C, et al. Discovery of Pyrazoloquinazoline Analogues as Orally Bioavailable KRAS-G12D Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02840

BibTeX
@article{Song2025,
  author = {Song, Jiyoung and Jang, Eunsung and Cho, Gyeonghi and Jung, Hoiyun and Cho, Minchang and Park, Chuneung and Kim, Jihun and Ki, Soyoung and Hong, Beomjin and Koh, Ilkyoo and Cho, Hyunho and Lim, Seona and Moon, Mi Jin and Hwang, Sungwan and Park, Hyun-Ju and Singh, Pargat and Kim, In Su},
  title = {Discovery of Pyrazoloquinazoline Analogues as Orally Bioavailable KRAS-G12D Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02840}
}
Kostenlos starten →